

AMENDMENTS TO THE CLAIMS

1. (Previously Presented) A method of treating or remedying psoriasis in a subject in need thereof, comprising administering to the subject a therapeutically effective dose of at least one calcitonin gene-related peptide (CGRP) antagonist compound in a pharmaceutically acceptable formulation.

2. (Currently Amended) The method according to claim 1, wherein the at least one CGRP antagonist compound is selected from the group consisting of: 4-sulfinyl benzamide compounds, 3,4-dinitrobenzamide compounds, benzamidazoliny l piperadine compounds, anti-CGRP antibodies, a peptide comprising ~~amino acids 8-37~~ of SEQ ID NO:1, tryptase active polypeptide, BIBN4096BS, and heparin.

3. (Previously Presented) The method according to claim 1, wherein the at least one CGRP antagonist compound is administered locally.

4. (Cancelled)

5. (Original) The method according to claim 1, wherein the CGRP antagonist compound is administered topically.

6-14. (Canceled)

15. (Previously Presented) The method according to claim 1, wherein the at least one CGRP antagonist is administered topically, dermally, intradermally, subcutaneously, via dermal infusion, or via subcutaneous infusion.

16-17. (Canceled)

18. (Currently Amended) The method according to claim 1, wherein said at least one CGRP antagonist compound comprises a polypeptide of ~~amino acids 8-37~~ of SEQ ID NO:1.

19. (Currently Amended) The method according to claim 1, wherein said at least one CGRP antagonist compound consists essentially of a polypeptide of ~~amino acids 8-37~~ of SEQ ID NO:1.

20. (Previously Presented) The method according to claim 1, wherein the at least one CGRP antagonist compound is a CGRP peptide which lacks wild type CGRP activity and binds to CGRP receptor.

21-22. (Canceled)